- Company
- Generics of Jardiance expected to compete for KRW 100B mkt
- by Kim, Jin-Gu Jul 2, 2025 06:08am
- The substance patent for Jardiance (empagliflozin), a diabetes treatment generating annual sales of approximately KRW 100 billion, is set to expire this October. Generic competition in the SGLT-2 inhibitor diabetes drug market is likely to heat up again. Approximately 50 companies have already secured approvals for related generic products
- Company
- Asthma drug 'Trelegy 200 Ellipta Inhaler' becomes available
- by Eo, Yun-Ho Jul 1, 2025 06:03am
- The asthma treatment 'Trelegy 200 Ellipta Inhaler' is now available for prescription at tertiary general hospitals. According to industry sources, Trelegy 200 Ellipta Inhaler (fluticasone furoate·umeclidinium·vilanterol) has passed the drug committees (DC) of Korea's 'Big 5' tertiary general hospitals, including Samsung Medical Center,
- Company
- Dong-A ST-Ipsen to comarket prostate cancer drug Diphereline
- by Son, Hyung Min Jul 1, 2025 06:02am
- Dong-A ST (CEO Jae-Hoon Jeong) announced on the 30th that it has signed a joint sales agreement with Ipsen Korea (CEO Mi-sun Yang) for the premature puberty and prostate cancer treatment ‘Diphereline.’ Diphereline is a GnRH (gonadotropin-releasing hormone) agonist developed by the multinational biopharmaceutical company Ipsen, used to
- Company
- Metabolic disease drug development landscape evolves
- by Son, Hyung Min Jul 1, 2025 06:02am
- Innovative efforts in the development of new drugs for metabolic disorders such as obesity and diabetes are steadily gaining traction in Korea and abroad. The success of standalone GLP-1 therapies has driven the evolution toward multi-hormonal agents, and recently, major global pharmaceutical companies and biotech firms are accelerating new drug
- Company
- AstraZeneca Korea launches ‘Lung Health Checkbus’ campaign
- by Whang, byung-woo Jul 1, 2025 06:00am
- AstraZeneca Korea announced on the 30th that it held a ceremony for the launch of its ‘Lung Health Checkbus’ campaign at the COEX Square in Seoul on the 27th. The campaign aims to help people detect lung nodules that they are not aware of at an early stage by operating buses equipped with AI-based chest X-ray imaging nationwide. Ast
- Company
- New K-drugs for metabolic diseases make international debut
- by Son, Hyung Min Jun 30, 2025 06:07am
- Major Korean pharmaceutical and biotechnology companies have signaled their full-scale entry into global clinical trials, presenting new drug development results at overseas conferences. The companies presented their achievements in developing new drugs for various metabolic diseases, including obesity, type 2 diabetes, and metabolic dysfunction
- Company
- Adempas may be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Jun 30, 2025 06:06am
- Adempas, a new treatment for pulmonary arterial hypertension that has emerged after a long wait, is now available for prescription at general hospitals in Korea. According to industry sources, Bayer Korea's Adempas (riociguat) has been approved by the Drug Committee (DC) of tertiary hospitals in Korea, including Samsung Medical Center and
- Opinion
- [Reporter's View] Divisional restructuring needed
- by Lee, Hye-Kyung Jun 30, 2025 06:06am
- During his candidacy, President Lee Jae-myung pledged to designate the biotech industry as a cutting-edge sector and build it as the future growth engine, aiming to position South Korea as one of the world's five strongest biotech countries. Based on an analysis that the previous government was short on investment in the pharmaceutical and bi
- Policy
- More generic 'Vimovo' drugs with naproxen+PPI enters the mkt
- by Lee, Tak-Sun Jun 30, 2025 06:05am
- Generic drugs containing the same active ingredients as the 'Vimovo' (naproxen+esomeprazole magnesium trihydrate), a combination of an anti-inflammatory drug and an anti-ulcer agent, are set to be released. A generic has not been approved since Chong Kun Dang's 'Naxen S Tab' was approved in 2024. Considering the characteristics of a generi
- Policy
- Polivy granted partial reimbursement after 5 years
- by Lee, Tak-Sun Jun 30, 2025 06:05am
- Roche’s Polivy (polatuzumab vedotin), a treatment for diffuse large B-cell lymphoma (DLBCL) that is currently non-reimbursed in Korea, has been added to the reimbursement list as a part of combination therapy. With the listing, the other drugs used in the combination, excluding Polivy, will be reimbursed. This measure is in accordance wi
